Healthcare Economist July 15, 2024
Jason Shafrin

Last week, the Federal Trade Commission (FTC) released a report titled “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies.” While I won’t get into an analysis of the specific arguments FTC made, the report does have a number of interesting statistics and graphics on pharmacy benefit managers (PBMs). Some highlights are below.

First, PBMs do much more than just design formularies. Now they are highly integrated entities, with many large PBMs being owned directly by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Pharma, Pharma / Biotech
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI
Sanofi adds new $600M manufacturing plant

Share This Article